Evidence map›Paper›PMID 40944500›Full record

ArticleTransfusion2025

Pathogen-reduced cryoprecipitate: Early experiences and inventory management.

C B Webb, A Javanbakht, D Hanna, S G Yates, R Zhang, S Afraz, R Sarode

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transfusion, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

C B WebbDepartment of Pathology, University of Texas Southwestern, Dallas, Texas, USA.ORCID https://orcid.org/0000-0002-2907-9993
A JavanbakhtDepartment of Pathology, University of Texas Southwestern, Dallas, Texas, USA.
D HannaTransfusion Services, University of Texas Southwestern, Dallas, Texas, USA.
S G YatesDepartment of Pathology, University of Texas Southwestern, Dallas, Texas, USA.ORCID https://orcid.org/0000-0001-9703-5047
R ZhangDepartment of Pathology, University of Texas Southwestern, Dallas, Texas, USA.
S AfrazDepartment of Pathology, University of Texas Southwestern, Dallas, Texas, USA.
R SarodeDepartment of Pathology, University of Texas Southwestern, Dallas, Texas, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRoom temperature storage of cryoprecipitated antihemophilic factor (CryoAHF) is limited to 6 h. Consequently, this product is stored frozen until requested, necessitating thawing and delaying fibrinogen supplementation. The FDA has approved the use of pathogen-reduced cryoprecipitated fibrinogen complex (PRCFC), which may be stored at room temperature up to 5 days. Opportunities for rapid dispensing of PRCFC and decreasing wastage were identified.

methodsOur institution implemented PRCFC in January 2022. Two to eight pools (1-4 doses) of PRCFC were maintained thawed at 20°C-24°C for rapid dispensing. A retrospective analysis of the turnaround time (TAT) to prepare and issue CryoAHF versus PRCFC orders was performed for orders between January 2022 and December 2024. Orders exceeding 60 min to issue were excluded from analysis as these reflected non-urgent orders or cryoprecipitate prepared in advance as part of massive transfusion protocols not released until later shipments.

resultsPRCFC was used in 40.3% of cryoprecipitate orders placed. Comparing PRCFC and CryoAHF, TAT reduction was significant for orders placed from the operating room, labor and delivery, and intensive care units, with reductions in time to prepare and issue of up to 50.0% and 47.7%, respectively (p < 0.001; p < 0.001). The longer shelf life of PRCFC led to a 54.2% reduction in cryoprecipitate wastage from 2021 to 2024.

conclusionPRCFC is ready to dispense and provides an immediate source of fibrinogen in critically bleeding patients with significant reductions in TAT. There is an added benefit of reduced wastage.

Indexed as

Blood PreservationFactor VIIIFibrinogenHumansRetrospective Studiescryoprecipitate coagulumFactor VIIIFibrinogentransfusion practices (adult)transfusion service operations

Identifiers

PMID40944500
PMCPMC12432805

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.